Capsulomics
Halethorpe, US · Maryland corporation · 3 known investors
Capsulomics offers Esopredict, a DNA methylation-based risk-stratification test that predicts progression from Barrett's esophagus to high-grade dysplasia or esophageal adenocarcinoma for gastroenterologists and pathologists. The test is used as a secondary option when the company's primary TissueCypher spatialomics test cannot provide results.
Founders & leadership
DL
Daniel LunzExecutive
WS
William StevensExecutive
SM
Stephen MeltzerNamed on SEC filing
Board
JN
John NeiderhuberBoard director
Investors · 3
Reported raises · per SEC filings
Form D private placements$2.4M disclosed across 1 round · 2019
▶$2.4MraisedMar 2025 · 10 investors · BiotechnologyRule 506(b)
▶$2.4MraisedMar 2025 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- John NeiderhuberDirector
- Daniel LunzExecutive Officer, Director
- William StevensExecutive Officer
- Stephen MeltzerDirector
- Offering amount
- $3M
- Amount sold
- $2.4M
- First sale
- Dec 2019
- Incorporated
- Corporation, Maryland
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Capsulomics do?
- Capsulomics offers Esopredict, a DNA methylation-based risk-stratification test that predicts progression from Barrett's esophagus to high-grade dysplasia or esophageal adenocarcinoma for gastroenterologists and pathologists. The test is used as a secondary option when the company's primary TissueCypher spatialomics test cannot provide results.
- Who are Capsulomics's investors?
- Capsulomics's investors include Early Light Ventures, Maryland TEDCO, TEDCO.
- How much funding has Capsulomics raised?
- Capsulomics has disclosed $2.4M raised across 1 round.
- Where is Capsulomics headquartered?
- Capsulomics is headquartered in Halethorpe, US.